valproic acid has been researched along with Stroke in 39 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 8.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 8.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 7.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "We report a case of stroke in a child with acquired protein C deficiency receiving valproic acid (VPA)." | 7.70 | Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. ( Balasa, V; Degrauw, A; Fogelson, H; Gartside, P; Glauser, T; Gruppo, R, 2000) |
| "Acute ataxia is commonly the chief complaint among patients visiting the emergency department (ED)." | 5.72 | A Phenytoin-Induced Ataxia Mimicking a Stroke. ( Urushidani, S, 2022) |
| "Levetiracetam (LEV) is an AED that is neuroprotective in various neurologic disorders." | 5.51 | Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study. ( Bao, XH; Wang, ZX; Xiong, H; Yuan, Y; Zhang, X; Zhang, Z; Zhao, DH; Zhao, XT, 2019) |
| "Overall, 1." | 5.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| "Acute treatment of stroke with histone deacetylase (HDAC) inhibitors has been shown to reduce ischemic cell damage; however, it is unclear whether delayed treatment with HDAC inhibitors will contribute to the brain repair and plasticity." | 5.38 | Valproic acid increases white matter repair and neurogenesis after stroke. ( Chen, C; Chopp, M; Cui, YS; Hozeska-Solgot, A; Jia, LF; Kassis, H; Liu, XS; Zhang, RL; Zhang, ZG, 2012) |
| "The mood stabilizers lithium, valproate and lamotrigine are traditionally used to treat bipolar disorder." | 4.87 | Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models. ( Chuang, DM; Fessler, EB; Wang, ZF, 2011) |
| "Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown." | 4.12 | Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke. ( Gao, X; Guo, Y; He, YY; Zeb, S; Zhang, HL; Zhou, XY; Zhu, YM, 2022) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 3.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder." | 3.91 | Mood stabilisers and risk of stroke in bipolar disorder. ( Chang, CK; Chen, CC; Chen, PH; Kuo, CJ; Pan, CH; Su, SS; Tsai, SY, 2019) |
| "We report a case of stroke in a child with acquired protein C deficiency receiving valproic acid (VPA)." | 3.70 | Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke. ( Balasa, V; Degrauw, A; Fogelson, H; Gartside, P; Glauser, T; Gruppo, R, 2000) |
| "Stroke is the leading cause of epilepsy in the elderly, ahead of degenerative diseases, tumors and head injuries." | 1.91 | Post-stroke seizures: risk factors and management after ischemic stroke. ( Derbali, H; Mansour, M; Messelmani, M; Mrissa, N; Mrissa, R; Ouerdiene, A; Zaouali, J, 2023) |
| "Specific antiseizure medications (ASM) would improve the outcome in post-stroke epilepsy (PSE)." | 1.72 | Efficacy and safety of antiseizure medication in post-stroke epilepsy. ( Groppa, S; Klimpe, S; Sandner, K; Stuckrad-Barre, SV; Uphaus, T; Winter, Y, 2022) |
| "Acute ataxia is commonly the chief complaint among patients visiting the emergency department (ED)." | 1.72 | A Phenytoin-Induced Ataxia Mimicking a Stroke. ( Urushidani, S, 2022) |
| "Carbamazepine was the second most common drug followed by lamotrigine and valproic acid." | 1.62 | Post-stroke epilepsy and antiepileptic drug use in men and women. ( Linnér, L; Loikas, D; Sundström, A; von Euler, M; Wettermark, B, 2021) |
| "Semiology of the most frequent seizures was motor focal in 82%, followed by focal motor with secondary bilateralization in 23%, focal discognitive in 13." | 1.51 | [Epilepsy in children with congenital hemiparesis secondary to perinatal ictus]. ( Alonso, X; Campistol, J; Escofet, C; Fons, C; Macaya, A; Revilla Orías, MD, 2019) |
| "Levetiracetam (LEV) is an AED that is neuroprotective in various neurologic disorders." | 1.51 | Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study. ( Bao, XH; Wang, ZX; Xiong, H; Yuan, Y; Zhang, X; Zhang, Z; Zhao, DH; Zhao, XT, 2019) |
| "Carbamazepine was the most chosen antiepileptic drug for secondary prophylaxis, followed by valproate acid, and levetiracetam." | 1.48 | [A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan]. ( Abe, S; Fukuma, K; Higashida, K; Ihara, M; Nagatsuka, K; Okuno, Y; Tanaka, T; Tomari, S; Toyoda, K; Yamagami, H, 2018) |
| "New-onset stroke was seen in three cases (10%) of the control group and in two cases (6." | 1.46 | Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke. ( Huang, HL; Wang, N; Xu, L; Yu, CY; Zhou, H, 2017) |
| "Hyperglycemia was induced by streptozotocin (STZ) injection 3 days before." | 1.42 | Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion. ( Abe, A; Aoki, J; Kimura, K; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Suda, S; Suzuki, K; Ueda, M, 2015) |
| "Overall, 1." | 1.42 | Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. ( Chan, L; Chi, NF; Chien, LN; Chiou, HY; Hu, CJ; Huang, YH; Kuan, YC, 2015) |
| " In addition, there appeared to be a dose-response relationship between stroke risk and PHT prescriptions." | 1.39 | Comparative stroke risk of antiepileptic drugs in patients with epilepsy. ( Hsieh, CY; Lai, EC; Lin, SJ; Yang, YH, 2013) |
| "Acute treatment of stroke with histone deacetylase (HDAC) inhibitors has been shown to reduce ischemic cell damage; however, it is unclear whether delayed treatment with HDAC inhibitors will contribute to the brain repair and plasticity." | 1.38 | Valproic acid increases white matter repair and neurogenesis after stroke. ( Chen, C; Chopp, M; Cui, YS; Hozeska-Solgot, A; Jia, LF; Kassis, H; Liu, XS; Zhang, RL; Zhang, ZG, 2012) |
| "Male rats underwent middle cerebral artery occlusion for 60 minutes followed by reperfusion for up to 14 days." | 1.38 | Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke. ( Chibane, F; Chuang, DM; Fessler, EB; Leeds, P; Leng, Y; Munasinghe, J; Tsai, LK; Wang, Z, 2012) |
| "The pathophysiology of cerebral ischemia involves multiple mechanisms including neuroinflammation mediated by activated microglia and infiltrating macrophages/monocytes." | 1.34 | Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. ( Chen, PS; Chuang, DM; Hong, JS; Kim, HJ; Ren, M; Rowe, M, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 7 (17.95) | 29.6817 |
| 2010's | 23 (58.97) | 24.3611 |
| 2020's | 8 (20.51) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Zeb, S | 1 |
| He, YY | 1 |
| Guo, Y | 1 |
| Zhu, YM | 1 |
| Zhou, XY | 1 |
| Zhang, HL | 1 |
| Winter, Y | 1 |
| Uphaus, T | 1 |
| Sandner, K | 1 |
| Klimpe, S | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Urushidani, S | 1 |
| Revilla Orías, MD | 1 |
| Alonso, X | 1 |
| Campistol, J | 1 |
| Macaya, A | 1 |
| Escofet, C | 1 |
| Fons, C | 1 |
| Tao, S | 1 |
| Sun, J | 1 |
| Hao, F | 1 |
| Tang, W | 1 |
| Li, X | 2 |
| Guo, D | 1 |
| Liu, X | 2 |
| Langenbruch, L | 1 |
| Meuth, SG | 1 |
| Wiendl, H | 1 |
| Mesters, R | 1 |
| Möddel, G | 1 |
| Demyanenko, SV | 1 |
| Dzreyan, VA | 1 |
| Uzdensky, AB | 1 |
| Loikas, D | 1 |
| Linnér, L | 1 |
| Sundström, A | 1 |
| Wettermark, B | 1 |
| von Euler, M | 1 |
| Ouerdiene, A | 1 |
| Messelmani, M | 1 |
| Derbali, H | 1 |
| Mansour, M | 1 |
| Zaouali, J | 1 |
| Mrissa, N | 1 |
| Mrissa, R | 1 |
| Holder, SD | 1 |
| Zhou, H | 1 |
| Wang, N | 1 |
| Xu, L | 1 |
| Huang, HL | 1 |
| Yu, CY | 1 |
| Brookes, RL | 1 |
| Crichton, S | 1 |
| Wolfe, CDA | 1 |
| Yi, Q | 1 |
| Li, L | 1 |
| Hankey, GJ | 1 |
| Rothwell, PM | 1 |
| Markus, HS | 2 |
| Faggi, L | 1 |
| Pignataro, G | 1 |
| Parrella, E | 1 |
| Porrini, V | 1 |
| Vinciguerra, A | 1 |
| Cepparulo, P | 1 |
| Cuomo, O | 1 |
| Lanzillotta, A | 1 |
| Mota, M | 1 |
| Benarese, M | 1 |
| Tonin, P | 1 |
| Annunziato, L | 1 |
| Spano, P | 1 |
| Pizzi, M | 1 |
| Bolland, MJ | 1 |
| Avenell, A | 1 |
| Gamble, G | 1 |
| Grey, A | 1 |
| Higashida, K | 1 |
| Tanaka, T | 1 |
| Yamagami, H | 1 |
| Tomari, S | 1 |
| Fukuma, K | 1 |
| Okuno, Y | 1 |
| Abe, S | 1 |
| Nagatsuka, K | 1 |
| Toyoda, K | 1 |
| Ihara, M | 1 |
| Thusius, N | 1 |
| Romanowicz, M | 1 |
| Mlynek, K | 1 |
| Sola, C | 1 |
| Chen, PH | 1 |
| Tsai, SY | 1 |
| Pan, CH | 1 |
| Chang, CK | 1 |
| Su, SS | 1 |
| Chen, CC | 1 |
| Kuo, CJ | 1 |
| Zhang, Z | 1 |
| Zhao, DH | 1 |
| Zhao, XT | 1 |
| Zhang, X | 1 |
| Xiong, H | 1 |
| Bao, XH | 1 |
| Yuan, Y | 1 |
| Wang, ZX | 1 |
| Suda, S | 3 |
| Katsura, K | 1 |
| Kanamaru, T | 1 |
| Saito, M | 2 |
| Katayama, Y | 3 |
| Katsura, KI | 1 |
| Kamiya, N | 1 |
| Dregan, A | 1 |
| Charlton, J | 1 |
| Wolfe, CD | 1 |
| Gulliford, MC | 1 |
| Ueda, M | 1 |
| Nito, C | 1 |
| Nishiyama, Y | 1 |
| Okubo, S | 1 |
| Abe, A | 1 |
| Aoki, J | 1 |
| Suzuki, K | 1 |
| Sakamoto, Y | 1 |
| Kimura, K | 1 |
| Özdemir, HH | 1 |
| Müngen, B | 1 |
| İlhan, S | 1 |
| Huang, YH | 1 |
| Chi, NF | 1 |
| Kuan, YC | 1 |
| Chan, L | 1 |
| Hu, CJ | 1 |
| Chiou, HY | 1 |
| Chien, LN | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 1 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Lippi, G | 1 |
| Targher, G | 1 |
| Franchini, M | 1 |
| Tsai, LK | 2 |
| Wang, Z | 2 |
| Munasinghe, J | 2 |
| Leng, Y | 2 |
| Leeds, P | 2 |
| Chuang, DM | 5 |
| Wang, ZF | 1 |
| Fessler, EB | 2 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Liu, XS | 1 |
| Chopp, M | 1 |
| Kassis, H | 1 |
| Jia, LF | 1 |
| Hozeska-Solgot, A | 1 |
| Zhang, RL | 1 |
| Chen, C | 1 |
| Cui, YS | 1 |
| Zhang, ZG | 1 |
| Chibane, F | 1 |
| Hsieh, CY | 1 |
| Lai, EC | 1 |
| Yang, YH | 1 |
| Lin, SJ | 1 |
| Kim, HJ | 1 |
| Rowe, M | 1 |
| Ren, M | 1 |
| Hong, JS | 1 |
| Chen, PS | 1 |
| Arnold, G | 1 |
| Schuh-Hofer, S | 1 |
| da Rocha, FF | 1 |
| Correa, H | 1 |
| Teixeira, AL | 1 |
| Dervaux, A | 1 |
| Levasseur, M | 1 |
| Alla, P | 1 |
| Philip, N | 1 |
| Azulay, JP | 1 |
| Attarian, S | 1 |
| Pouget, J | 1 |
| Gruppo, R | 1 |
| Degrauw, A | 1 |
| Fogelson, H | 1 |
| Glauser, T | 1 |
| Balasa, V | 1 |
| Gartside, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
5 reviews available for valproic acid and Stroke
| Article | Year |
|---|---|
Psychotic and Bipolar Disorders: Bipolar Disorder.
Topics: Antimanic Agents; Bipolar Disorder; Cardiovascular Diseases; Chronic Pain; Comorbidity; Family Pract | 2017 |
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
Beneficial effects of mood stabilizers lithium, valproate and lamotrigine in experimental stroke models.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Disease Models, Animal; Humans; Lamotrigine; Lithiu | 2011 |
The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials.
Topics: Affect; Animals; Antimanic Agents; Apoptosis; Excitatory Amino Acid Agonists; Humans; Lithium; N-Met | 2005 |
[Comorbidities in migraine patients].
Topics: Adult; Amitriptyline; Analgesics, Non-Narcotic; Anticonvulsants; Anxiety Disorders; Carotid Artery, | 2007 |
1 trial available for valproic acid and Stroke
| Article | Year |
|---|---|
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Ischemia; Disease-Free Survival; Female; Follow-Up S | 2018 |
33 other studies available for valproic acid and Stroke
| Article | Year |
|---|---|
Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke.
Topics: Animals; Astrocytes; Brain Ischemia; Glial Fibrillary Acidic Protein; Gliosis; Histones; Ischemic St | 2022 |
Efficacy and safety of antiseizure medication in post-stroke epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Lacosamide; Lamotrigine; Levetiracetam; Seiz | 2022 |
A Phenytoin-Induced Ataxia Mimicking a Stroke.
Topics: Ataxia; Carbamazepine; Female; Humans; Middle Aged; Phenytoin; Stroke; Valproic Acid | 2022 |
[Epilepsy in children with congenital hemiparesis secondary to perinatal ictus].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsy; Female; Humans; Infan | 2019 |
Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy.
Topics: Aged; Anticonvulsants; Biomarkers; Brain; Case-Control Studies; Down-Regulation; Drug Therapy, Combi | 2020 |
Clinically relevant interaction of rivaroxaban and valproic acid - A case report.
Topics: Administration, Oral; Adult; Anticoagulants; Anticonvulsants; Atrial Fibrillation; Factor Xa Inhibit | 2020 |
Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate.
Topics: Animals; Cerebral Cortex; Gene Expression; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Hi | 2020 |
Post-stroke epilepsy and antiepileptic drug use in men and women.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigin | 2021 |
Post-stroke seizures: risk factors and management after ischemic stroke.
Topics: Aged; Epilepsy; Female; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Middle Ag | 2023 |
Clinical study on anti-epileptic drug with B vitamins for the treatment of epilepsy after stroke.
Topics: Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Male; Middle Aged; Stroke; Valproic Acid; Vi | 2017 |
Synergistic Association of Valproate and Resveratrol Reduces Brain Injury in Ischemic Stroke.
Topics: Acetylation; Animals; Bcl-2-Like Protein 11; Disease Models, Animal; Drug Synergism; Histone Deacety | 2018 |
Reader response: Expression of Concern: Does compensatory hyperparathyroidism predispose to ischemic stroke? Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy; An alternative to vitamin D supplementation to pre
Topics: Adult; Bone Density; Bone Remodeling; Brain Ischemia; Dietary Supplements; Epilepsy; Humans; Hyperpa | 2018 |
[A nationwide multi-center questionnaire survey on the management and treatment of post-stroke seizure and epilepsy in Japan].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Japan; Levetiracetam; Male; Piracetam; Sei | 2018 |
Prolonged Psychosis Associated with Left Insular Stroke: Talking to God in the Walls.
Topics: Aged; Antimanic Agents; Antipsychotic Agents; Cerebral Cortex; Electroencephalography; Hallucination | 2018 |
Mood stabilisers and risk of stroke in bipolar disorder.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cross-O | 2019 |
Levetiracetam administration is correlated with lower mortality in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes: a retrospective study.
Topics: Acidosis, Lactic; Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Female; Human | 2019 |
Valproic acid attenuates ischemia-reperfusion injury in the rat brain through inhibition of oxidative stress and inflammation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Brain Ischemia; Disease Models, Animal; In Situ Nic | 2013 |
Valproic acid enhances the effect of bone marrow-derived mononuclear cells in a rat ischemic stroke model.
Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Brain Ischemia; Combined Modality Therapy; | 2014 |
Is sodium valproate, an HDAC inhibitor, associated with reduced risk of stroke and myocardial infarction? A nested case-control study.
Topics: Aged; Aged, 80 and over; Bias; Brain Ischemia; Case-Control Studies; Databases, Factual; Electronic | 2014 |
Valproic acid ameliorates ischemic brain injury in hyperglycemic rats with permanent middle cerebral occlusion.
Topics: Animals; Blood Glucose; Brain; Brain Ischemia; Hyperglycemia; Infarction, Middle Cerebral Artery; Ma | 2015 |
Evaluation of the efficacy of sodium valproate in convulsive status epilepticus following to ıschemic stroke.
Topics: Administration, Intravenous; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; | 2015 |
Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cohort Studies; Female; Humans; Male | 2015 |
Migraine, valproic acid, and lipoprotein(a).
Topics: Analgesics; Child; Humans; Lipoprotein(a); Migraine Disorders; Risk Factors; Stroke; Valproic Acid | 2009 |
Mesenchymal stem cells primed with valproate and lithium robustly migrate to infarcted regions and facilitate recovery in a stroke model.
Topics: Animals; Cell Movement; Infarction, Middle Cerebral Artery; Lithium; Mesenchymal Stem Cell Transplan | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Valproic acid increases white matter repair and neurogenesis after stroke.
Topics: Animals; Brain; Histone Deacetylase Inhibitors; Immunohistochemistry; In Situ Nick-End Labeling; Mal | 2012 |
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Topics: Animals; Anticonvulsants; Blotting, Western; Brain Ischemia; Cerebral Infarction; Hypoxia-Inducible | 2012 |
Comparative stroke risk of antiepileptic drugs in patients with epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Male | 2013 |
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Topics: Animals; Anti-Inflammatory Agents; Brain; Brain Ischemia; Butyrates; CD11b Antigen; Cerebral Infarct | 2007 |
A successful outcome with valproic acid in a case of mania secondary to stroke of the right frontal lobe.
Topics: Anticonvulsants; Bipolar Disorder; Female; Frontal Lobe; Humans; Middle Aged; Stroke; Treatment Outc | 2008 |
Risperidone and valproate for mania following stroke.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Humans; Male; Middle Aged; Risperidone; Str | 2008 |
[Epilepsy in an adult with chromosome 22q11 micro-deletion].
Topics: Adult; Anticonvulsants; Atrophy; Brain; Chromosome Deletion; Chromosomes, Human, Pair 22; DiGeorge S | 1999 |
Protein C deficiency related to valproic acid therapy: a possible association with childhood stroke.
Topics: Anticonvulsants; Antithrombins; Child; Child, Preschool; Female; Fibrinogen; Humans; Infant; Platele | 2000 |